title: Use of MenACWY-CRM in adolescents in the United States.
abstract: Adolescents constitute a high-risk group for invasive meningococcal disease. MenACWY-CRM (Menveo, Novartis Vaccines, Cambridge, MA) is a quadrivalent meningococcal conjugate vaccine indicated to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y. It has been approved for use in persons age 2-55 years. The tolerability and immunogenicity of MenACWY-CRM in adolescents have been ascertained in phase 2 and 3 trials against MPSV4 (Menomune, sanofi pasteur, Swiftwater, PA), an unconjugated quadrivalent meningococcal vaccine, and MenACWY-D (Menactra, sanofi pasteur), another conjugated quadrivalent meningococcal vaccine. Clinical trials also have demonstrated that MenACWY-CRM is well tolerated and immunogenic when administered to adolescents concomitantly with the combined tetanus, diphtheria, and acellular pertussis vaccine (Boostrix, GlaxoSmithKline Biologicals, Rixensart, Belgium) and the quadrivalent human papillomavirus vaccine (Gardasil, Merck & Co., Inc., Whitehouse Station, NJ).
authors.affiliation: Department of Pediatrics, Center for Global Health and Division of Infectious Diseases, Cincinnati Children's Hospital, OH, USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Black
authors.forename: Stan L
authors.initials: SL
authors.lastname: Block
mesh_terms: D000293:Adolescent; D002648:Child; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D006801:Humans; D008297:Male; D008589:Meningococcal Infections / Q000503:physiopathology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000627:therapeutic use*; D009345:Neisseria meningitidis / Q000276:immunology; D014481:United States; D018074:Vaccines, Conjugate / Q000627:therapeutic use
chemical_list: C525703:MenACWY; C568160:MenACWY-D vaccine; D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate